Galantamine in frontotemporal dementia and primary progressive aphasia.

  title={Galantamine in frontotemporal dementia and primary progressive aphasia.},
  author={Andrew Kertesz and Darlyne Morlog and Melanie Light and Mervin Blair and Wilda Davidson and Sarah Jesso and Ryan Brashear},
  journal={Dementia and geriatric cognitive disorders},
  volume={25 2},
BACKGROUND/AIMS The treatment of frontotemporal dementia (FTD) has been mainly symptomatic. Small randomized or open-label case control studies of neurotransmitters have been inconclusive. We tried galantamine in the 2 most common varieties of FTD. METHOD Thirty-six behavioral variety FTD and primary progressive aphasia (PPA) patients were treated in an open-label period of 18 weeks and a randomized, placebo-controlled phase for 8 weeks with galantamine. The primary efficacy measures were the… CONTINUE READING